JP2004504388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504388A5 JP2004504388A5 JP2002514115A JP2002514115A JP2004504388A5 JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5 JP 2002514115 A JP2002514115 A JP 2002514115A JP 2002514115 A JP2002514115 A JP 2002514115A JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- phenyl
- dichloro
- amide according
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001408 amides Chemical class 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Chemical group 0.000 claims 14
- 239000001301 oxygen Substances 0.000 claims 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000005842 heteroatoms Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004432 carbon atoms Chemical group C* 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052757 nitrogen Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- XTDQXQIDBRVLFJ-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(oxan-4-yloxy)-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCOCC1 XTDQXQIDBRVLFJ-UHFFFAOYSA-N 0.000 claims 1
- MIEVEFJYIVXWLB-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-N-(methylcarbamoyl)-2-(oxan-4-yloxy)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCOCC1 MIEVEFJYIVXWLB-UHFFFAOYSA-N 0.000 claims 1
- LNNBWXQTZQJUMS-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-N-(4,5-dihydro-1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SCCN=1)OC1C=CCCC1 LNNBWXQTZQJUMS-UHFFFAOYSA-N 0.000 claims 1
- AKTVVVWFNHFFQE-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-N-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 AKTVVVWFNHFFQE-UHFFFAOYSA-N 0.000 claims 1
- CNNNBBYSLRJXCB-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 CNNNBBYSLRJXCB-UHFFFAOYSA-N 0.000 claims 1
- GDLVELQZXTUWHH-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-N-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 GDLVELQZXTUWHH-UHFFFAOYSA-N 0.000 claims 1
- OKVVHUTYWMKAMT-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1C=CCCC1 OKVVHUTYWMKAMT-UHFFFAOYSA-N 0.000 claims 1
- GBRFVNIVLOASHK-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-N-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 GBRFVNIVLOASHK-UHFFFAOYSA-N 0.000 claims 1
- MMNSTTDMQWXPIG-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCCC1 MMNSTTDMQWXPIG-UHFFFAOYSA-N 0.000 claims 1
- PZDFZWWTLUQGLV-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-N-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCCC1 PZDFZWWTLUQGLV-UHFFFAOYSA-N 0.000 claims 1
- POASZSTXBAHPDO-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 POASZSTXBAHPDO-UHFFFAOYSA-N 0.000 claims 1
- AQFOGDIAJYVUPT-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-N-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 AQFOGDIAJYVUPT-UHFFFAOYSA-N 0.000 claims 1
- VDMFSJBFMOBHGB-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-N-pyridin-2-ylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1N=CC=CC=1)OC1CCCC1 VDMFSJBFMOBHGB-UHFFFAOYSA-N 0.000 claims 1
- WAUWSYSGLFXHRD-UHFFFAOYSA-N 2-cyclopentylsulfonyl-2-(3,4-dichlorophenyl)-N-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(S(=O)(=O)C1CCCC1)C(=O)NC1=NC=CS1 WAUWSYSGLFXHRD-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- UMLQXVZOFOAQFB-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-3-oxo-N-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)C1CCCC1)C(=O)NC1=NC=CS1 UMLQXVZOFOAQFB-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal alkoxide Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000005595 deprotonation Effects 0.000 claims 1
- 238000010537 deprotonation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Claims (24)
- 式(I):
R1及びR2は、独立に、水素、ハロ、シアノ、ニトロ、低級アルキルチオ、ペルフルオロ低級アルキルチオ、低級アルキルスルホニル、又はペルフルオロ低級アルキルスルホニルであり;
R3は、2〜4個の炭素原子を有する低級アルキル、あるいはシクロアルキル、シクロアルケニル、または酸素若しくは硫黄から選択される1個のヘテロ原子を有するヘテロシクロアルキルである、5員〜7員環であり;
R4は、−C(O)NHR5であるか、又はR6であり;
R5は、水素、低級アルキル、低級アルケニル、ヒドロキシ低級アルキル、ハロ低級アルキル、−(CH2)n−C(O)−OR7、−C(O)−(CH2)n−C(O)−OR8であり;
R6は、環炭素原子により、示されるアミド基に連結している、非置換又は単置換の5員又は6員ヘテロ芳香環であって、そしてこの5員又は6員ヘテロ芳香環は、硫黄、酸素又は窒素から選択される1〜3個のヘテロ原子を含み(ここで1個のヘテロ原子は、連結環炭素原子に隣接した窒素であり;該単置換ヘテロ芳香環は、該連結炭素原子に隣接していない環炭素原子の位置で、低級アルキル、ハロ、ニトロ、シアノ、−(CH2)n−OR9、−(CH2)n−C(O)−OR10、−(CH2)n−C(O)−NH−R11、−C(O)−C(O)−OR12、−(CH2)n−NHR13よりなる群から選択される置換基で単置換されている);
nは、0、1、2、3又は4であり;
R7、R8、R9、R10、R11、R12及びR13は、独立に、水素又は低級アルキルであり;
Xは、酸素、硫黄、スルホニル又はカルボニルであり;
*は、不斉炭素原子を示す〕で示される化合物及びその薬剤学的に許容しうる塩よりなる群から選択されるアミド。 - 該化合物が、式(III):
R3は、シクロアルキル、シクロアルケニル、又は酸素若しくは硫黄から選択される1個のヘテロ原子を有するヘテロシクロアルキルである、5員〜7員環であり;
R6は、環炭素原子により、示されるアミド基に連結している、非置換の5員又は6員ヘテロ芳香環であって、そしてこの5員又は6員ヘテロ芳香環は、硫黄、酸素又は窒素から選択される1〜3個のヘテロ原子を含み(ここで1個のヘテロ原子は、連結環炭素原子に隣接した窒素である);そして
Xは、酸素、硫黄、スルホニル又はカルボニルである〕で示される、請求項1記載のアミド。 - R5が、低級アルキルである、請求項1記載のアミド。
- R5が、メチルである、請求項1又は2のいずれか1項記載のアミド。
- R6が、ピラジニル、ピリダジニル、イソオキサゾリル、イソチアゾリル、ピラゾリル、ピリジニル、ピリミジニル、チアジアゾリル、トリアジニル、チアゾリル、オキサゾリル、又はイミダゾリル、好ましくはチアゾリル又はピリジニルである、請求項1又は3のいずれか1項記載のアミド。
- R6が、チアゾリルである、請求項1又は3のいずれか1項記載のアミド。
- R6が、ピリジニルである、請求項1又は3のいずれか1項記載のアミド。
- R1及びR2が、独立に、ハロ又は低級アルキルスルホニルである、請求項1〜8のいずれか1項記載のアミド。
- R1及びR2が、独立に、クロロ又はメチルスルホニルである、請求項1〜8のいずれか1項記載のアミド。
- R1及びR2が、クロロである、請求項1〜8のいずれか1項記載のアミド。
- R1が、クロロであり、そしてR2が、メチルスルホニルである、請求項1〜8のいずれか1項記載のアミド。
- R3が、シクロペンチル、シクロヘキシル、シクロヘキセニル、又は酸素若しくは硫黄から選択される1個のヘテロ原子を有する6員ヘテロシクロアルキルである、請求項1〜12のいずれか1項記載のアミド。
- 該ヘテロ原子が、酸素である、請求項13記載のアミド。
- R3が、シクロペンチルである、請求項1〜14のいずれか1項記載のアミド。
- Xが、酸素である、請求項1〜15のいずれか1項記載のアミド。
- Xが、硫黄、スルホニル又はカルボニルである、請求項1〜15のいずれか1項記載のアミド。
- 1−〔シクロペンチルオキシ−(3,4−ジクロロ−フェニル)−アセチル〕−3−メチル−尿素、
1−〔シクロヘキシルオキシ−(3,4−ジクロロ−フェニル)−アセチル〕−3−メチル−尿素、
1−〔(シクロヘキサ−2−エニルオキシ)−(3,4−ジクロロ−フェニル)−アセチル〕−3−メチル−尿素、
1−〔(3,4−ジクロロ−フェニル)−(テトラヒドロ−ピラン−4−イルオキシ)−アセチル〕−3−メチル−尿素、
1−〔(3−クロロ−4−メタンスルホニル−フェニル)−シクロペンチルオキシ−アセチル〕−3−メチル−尿素、
1−〔(3−クロロ−4−メタンスルホニル−フェニル)−(シクロヘキサ−2−エニルオキシ)−アセチル〕−3−メチル−尿素、
2−(3,4−ジクロロ−フェニル)−2−(テトラヒドロ−ピラン−4−イルオキシ)−N−チアゾール−2−イル−アセトアミド、
2−シクロペンチルオキシ−2−(3,4−ジクロロ−フェニル)−N−チアゾール−2−イル−アセトアミド、
2−シクロヘキシルオキシ−2−(3,4−ジクロロ−フェニル)−N−チアゾール−2−イル−アセトアミド、
2−(シクロヘキサ−2−エニルオキシ)−2−(3,4−ジクロロ−フェニル)−N−チアゾール−2−イル−アセトアミド、
2−シクロペンチルオキシ−2−(3,4−ジクロロ−フェニル)−N−ピリジン−2−イル−アセトアミド、
2−(3−クロロ−4−メタンスルホニル−フェニル)−2−シクロペンチルオキシ−N−チアゾール−2−イル−アセトアミド、
2−(3−クロロ−4−メタンスルホニル−フェニル)−2−(シクロヘキサ−2−エニルオキシ)−N−(4,5−ジヒドロ−チアゾール−2−イル)−アセトアミド、
3−シクロペンチル−2−(3,4−ジクロロ−フェニル)−3−オキソ−N−チアゾール−2−イル−プロピオンアミド、
2−シクロペンタンスルホニル−2−(3,4−ジクロロ−フェニル)−N−チアゾール−2−イル−アセトアミド、及び
2−シクロペンチルスルファニル−2−(3,4−ジクロロ−フェニル)−N−チアゾール−2−イル−アセトアミドよりなる群から選択される、請求項1〜17のいずれか1項記載のアミド。 - 請求項1〜18のいずれか1項記載の化合物、並びに薬剤学的に許容しうる担体及び/又は補助剤を含むことを特徴とする、薬剤組成物。
- 請求項1〜18のいずれか1項記載の式(I)の化合物を、薬剤学的に許容しうる担体及び/又は補助剤と合わせることを特徴とする、請求項19記載の薬剤組成物の製造方法。
- 治療活性物質として使用するための、請求項1〜18のいずれか1項記載の化合物。
- II型糖尿病の治療又は予防用医薬の製造のための、請求項1〜18のいずれか1項記載の化合物の使用。
- 請求項1〜18のいずれか1項記載のアミドの製造方法であって、
(a)式(14):
(b)式(18):
(c)式(14):
(d)式(15):
(e)式(12):
(f)式(III):
(g)式(II):
を特徴とする方法。 - 請求項23記載の方法により製造される化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21987200P | 2000-07-20 | 2000-07-20 | |
PCT/EP2001/007994 WO2002008209A1 (en) | 2000-07-20 | 2001-07-11 | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004504388A JP2004504388A (ja) | 2004-02-12 |
JP2004504388A5 true JP2004504388A5 (ja) | 2005-02-17 |
JP4138478B2 JP4138478B2 (ja) | 2008-08-27 |
Family
ID=22821104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002514115A Expired - Fee Related JP4138478B2 (ja) | 2000-07-20 | 2001-07-11 | アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター |
Country Status (21)
Country | Link |
---|---|
US (2) | US6486184B2 (ja) |
EP (1) | EP1305301B1 (ja) |
JP (1) | JP4138478B2 (ja) |
KR (1) | KR100556323B1 (ja) |
CN (1) | CN1184214C (ja) |
AR (1) | AR032626A1 (ja) |
AT (1) | ATE297907T1 (ja) |
AU (2) | AU8760001A (ja) |
BR (1) | BR0112658A (ja) |
CA (1) | CA2416229C (ja) |
DE (1) | DE60111534T2 (ja) |
DK (1) | DK1305301T3 (ja) |
ES (1) | ES2243547T3 (ja) |
GT (1) | GT200100146A (ja) |
MX (1) | MXPA03000365A (ja) |
PA (1) | PA8522701A1 (ja) |
PE (1) | PE20020335A1 (ja) |
PT (1) | PT1305301E (ja) |
UY (1) | UY26850A1 (ja) |
WO (1) | WO2002008209A1 (ja) |
ZA (1) | ZA200300173B (ja) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EP1336607A1 (en) * | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
CN100506807C (zh) | 2001-12-21 | 2009-07-01 | 诺沃挪第克公司 | 作为gk活化剂的酰胺衍生物 |
UA80427C2 (en) | 2002-04-26 | 2007-09-25 | Hoffmann La Roche | Substituted phenylacetamides and their use as glucokinase activators |
KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
AU2005229415B2 (en) | 2004-04-02 | 2009-05-14 | Novartis Ag | Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
CA2560689C (en) | 2004-04-02 | 2011-03-01 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes |
MXPA06012008A (es) * | 2004-04-21 | 2007-01-25 | Prosidion Ltd | Compuestos de amida tri(ciclo) sustituidos. |
EP1758575A1 (en) | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
KR20080105180A (ko) * | 2004-08-12 | 2008-12-03 | 프로시디온 리미티드 | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도 |
EP1904466A1 (en) * | 2005-07-08 | 2008-04-02 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
ATE547396T1 (de) | 2005-07-08 | 2012-03-15 | Novo Nordisk As | Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren |
WO2007006814A1 (en) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Urea glucokinase activators |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
US20090281142A1 (en) | 2005-08-31 | 2009-11-12 | Astellas Pharma Inc. | Thiazole derivative |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
BRPI0617207A2 (pt) | 2005-09-29 | 2011-07-19 | Sanofi Aventis | derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
JP2009514835A (ja) * | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
SI1951658T1 (sl) | 2005-11-17 | 2012-11-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja priprava interapevtska uporaba |
EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
CA2669874A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
JP2010515701A (ja) | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
CA2679185A1 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
TW200902489A (en) * | 2007-03-07 | 2009-01-16 | Kyorin Seiyaku Kk | Glucokinase-activating substance |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
US8501955B2 (en) | 2007-10-08 | 2013-08-06 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal application |
AR070107A1 (es) * | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
KR20100113518A (ko) | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
EP2275414B1 (en) | 2008-04-28 | 2015-06-10 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
GEP20135783B (en) | 2008-05-16 | 2013-03-11 | Takeda California Inc | Glucokinase activators |
US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
CA2768232A1 (en) | 2009-07-31 | 2011-02-03 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
AU2011231503C1 (en) | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
CN105176930B (zh) | 2010-03-31 | 2021-05-04 | 斯克里普斯研究所 | 重编程细胞 |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
BR112013024076A2 (pt) | 2011-03-28 | 2016-12-06 | Novo Nordisk As | análogos de glucagon |
RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
CN111032680A (zh) | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | 能够与黑皮质素4受体结合的双环化合物 |
US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
JPS5564592A (en) * | 1978-11-10 | 1980-05-15 | Teijin Ltd | Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it |
JPS62153273A (ja) * | 1985-12-26 | 1987-07-08 | Tokuyama Soda Co Ltd | ピラゾ−ル化合物 |
MXPA01009814A (es) * | 1999-03-29 | 2002-04-24 | Hoffmann La Roche | Activadores de la glucoquinasa. |
-
2001
- 2001-07-11 MX MXPA03000365A patent/MXPA03000365A/es active IP Right Grant
- 2001-07-11 EP EP01967150A patent/EP1305301B1/en not_active Expired - Lifetime
- 2001-07-11 WO PCT/EP2001/007994 patent/WO2002008209A1/en active IP Right Grant
- 2001-07-11 DE DE60111534T patent/DE60111534T2/de not_active Expired - Lifetime
- 2001-07-11 JP JP2002514115A patent/JP4138478B2/ja not_active Expired - Fee Related
- 2001-07-11 PT PT01967150T patent/PT1305301E/pt unknown
- 2001-07-11 KR KR1020037000822A patent/KR100556323B1/ko not_active IP Right Cessation
- 2001-07-11 CA CA002416229A patent/CA2416229C/en not_active Expired - Fee Related
- 2001-07-11 DK DK01967150T patent/DK1305301T3/da active
- 2001-07-11 CN CNB01813050XA patent/CN1184214C/zh not_active Expired - Fee Related
- 2001-07-11 BR BR0112658-0A patent/BR0112658A/pt not_active IP Right Cessation
- 2001-07-11 AU AU8760001A patent/AU8760001A/xx active Pending
- 2001-07-11 AT AT01967150T patent/ATE297907T1/de not_active IP Right Cessation
- 2001-07-11 ES ES01967150T patent/ES2243547T3/es not_active Expired - Lifetime
- 2001-07-11 AU AU2001287600A patent/AU2001287600B2/en not_active Ceased
- 2001-07-13 US US09/905,152 patent/US6486184B2/en not_active Expired - Fee Related
- 2001-07-18 PA PA20018522701A patent/PA8522701A1/es unknown
- 2001-07-18 AR ARP010103437A patent/AR032626A1/es active IP Right Grant
- 2001-07-19 PE PE2001000731A patent/PE20020335A1/es not_active Application Discontinuation
- 2001-07-19 UY UY26850A patent/UY26850A1/es not_active Application Discontinuation
- 2001-07-20 GT GT200100146A patent/GT200100146A/es unknown
-
2002
- 2002-06-25 US US10/179,717 patent/US6608218B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 ZA ZA200300173A patent/ZA200300173B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004504388A5 (ja) | ||
JP2004521095A5 (ja) | ||
RU2002118339A (ru) | Транс-олефиновые активаторы глюкокиназы | |
RU2005113719A (ru) | Производные индол-3-карбоксамида в качестве активаторов глюкокиназы | |
JP2006515858A5 (ja) | ||
CA2430579A1 (en) | Isoindolin-1-one glucokinase activators | |
JP2004504301A5 (ja) | ||
CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
WO1992009279A1 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
CA2509086A1 (en) | Substituted arylcyclopropylacetamides as glucokinase activators | |
CA2407428A1 (en) | Hydantoin-containing glucokinase activators | |
WO2011035900A1 (en) | New thiadiazole derivatives | |
RU98100866A (ru) | Ароматические соединения и содержащие их фармацевтические композиции | |
CA2392570A1 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
CA2683738A1 (en) | Indanone derivatives that inhibit prolyl hydroxylase | |
JP2004502670A5 (ja) | ||
CA2369560A1 (en) | Agent for prophylaxis and treatment of liver disease | |
JP2005526696A5 (ja) | ||
RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
RU2367659C2 (ru) | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) | |
WO2004093806A3 (en) | Compounds for the treatment of metabolic disorders | |
JP2005515976A5 (ja) | ||
RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy |